(Q48722794)

15 February 2018

title

Actigraphic monitoring (actigraphy) of circadian locomotor activity in schizophrenic patients with acute neuroleptic-induced akathisia (English)

1 reference

15 February 2018

0 references

0 references

7

Weizman A

1 reference

15 February 2018

author name string

Poyurovsky M

1

1 reference

15 February 2018

Nave R

2

1 reference

15 February 2018

Epstein R

3

1 reference

15 February 2018

Tzischinsky O

4

1 reference

15 February 2018

Schneidman M

5

1 reference

15 February 2018

Barnes TR

6

1 reference

15 February 2018

Lavie P

8

1 reference

15 February 2018

language of work or name

English

0 references

publication date

1 May 2000

1 reference

15 February 2018

European Neuropsychopharmacology

published in

1 reference

15 February 2018

volume

10

1 reference

15 February 2018

issue

3

1 reference

15 February 2018

page(s)

171-176

1 reference

15 February 2018

A rating scale for drug-induced akathisia

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900063-8

7 January 2021

An electromyographic marker for neuroleptic-induced akathisia: preliminary measures of sensitivity and specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900063-8

7 January 2021

Quantitative assessment of psychomotor activity in patients with neuroleptic-induced akathisia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900063-8

7 January 2021

Diurnal variation in tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900063-8

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900063-8

7 January 2021

Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900063-8

7 January 2021

Polysomnographic Characteristics of Neuroleptic-Induced Akathisia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900063-8

7 January 2021

Mianserin and restless legs

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900063-8

7 January 2021

Circadian pattern of acute, neuroleptic-induced dystonic reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900063-8

7 January 2021

Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900063-8

7 January 2021

Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900063-8

7 January 2021

Complicating factors in the analysis of acute drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900063-8

7 January 2021

Actigraphy and motion analysis: new tools for psychiatry

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900063-8

7 January 2021

Why do schizophrenic patients refuse to take their drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2800%2900063-8

7 January 2021

10.1016/S0924-977X(00)00063-8

Identifiers

DOI

1 reference

15 February 2018

1 reference

15 February 2018